Factsheet and Information Brochure
Factsheet
Target Market
Costs and charges
Fund rules (136 kB)
Prospectus (1596 kB)
Periodic reports
Sustainability SFDR (1071 kB)
Annual review (PF) (3188 kB)
Semi-annual report (PF) (186 kB)
Marketing material
Brief fund information
Summary SFDR (168 kB)
Pre-contractual SFDR
Pre-contractual SFDR (1146 kB)
AstraZeneca Allemansfond
Legal name: AstraZeneca Allemansfond
Equity Fund Registered in Sweden (Non-UCITS)
Bid
About risk
Historical yields are not a guarantee of future returns. A fund can both increase and decrease in value and it is not guaranteed that you will recover the entire invested amount. Note that a fund with risk level 5-7, as stated in the fund's fact sheet (KID), can vary greatly in value due to the fund's composition and management methodology. The prospectus, fund rules and KID are available under each fund. Summary of investors' rights.
The fund is actively managed special fund (non-UCITS) and thereby the fund deviates from a UCITS fund by concentrating holdings to a smaller number of equities issued by companies in primarily Sweden. The fund invests a significant amount (maximum of 50% of assets) in AstraZeneca.
For this fund, the fund company's Enhanced exclusion level applies. For information about sectors that the fund excludes, see the Detailed information tab.
The fund is reported as an Article 8 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).
For this fund, the fund company's Enhanced exclusion level applies. For information about sectors that the fund excludes, see the Detailed information tab.
The fund is reported as an Article 8 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).
Fund manager
Ulrika Orstadius Experience in the fund industry 2011. Portfolio Manager since 1 November 2022.
|
|
||
|---|---|---|---|
|
The risk indicator provides guidance on the risk level for this product relative to other financial products. It shows the likelihood that the product will decrease in value due to market performance. Risk level 1 represents a low risk and risk level 7 is a high risk.
|
|
30.09.2025
|
||
|---|---|---|---|
|
The rating shows which funds have historically posted the strongest performance in relation to risk. Ratings are denoted by a scale of one to five stars, with five as the highest rating. A fund must have a performance history of at least three years to receive a rating.
Read more about the fund's rating |
|
|
||
|---|---|---|---|
|
This fund promotes environmental and social characteristics through its investments but does not have sustainable investments as its objective. As a result, the fund takes into consideration the environment and climate, as well as human rights, employees’ rights and corruption. The fund is reported as an Article 8 fund pursuant to EU regulation on sustainability-related disclosures in the financial services sector (SFDR). |
|
31.07.2025
|
|||
|---|---|---|---|
|
The sustainability rating is developed by the fund information company Morningstar. The rating measures how well the fund's investee companies manage sustainability risks relative to other funds within the same global Morningstar category. If the fund has invested in government bonds issued by sovereign states, the respective country's sustainability risk is included in the calculation. The analyzed funds can receive a sustainability rating between 1 and 5 globes, with 5 as the highest rating. The fund complies with the UN Principles for Responsible Investments. |
Graph
Performance
| Rate 24.10.2025 | 1 week | 1 month | 3 months | 2025 | 1 year | 5 years | 10 years |
|---|---|---|---|---|---|---|---|
| 4,221.36 SEK | 0.80% | 6.25% | 6.35% | 9.35% | 3.28% | 91.33% | 248.40% |
Portfolio 09.10.2025
Portfolio manager comments — Q3 2025
The fund increased during the period, in line with its benchmark index, the SIX Sweden SRI Index GI (60%). The key positive contributors to the fund’s performance during the period were AstraZeneca, Sandvik, and Hexagon. AstraZeneca delivered strong results, supported by a quarterly report showing solid growth in its oncology portfolio and by positive outcomes from clinical trials. Sandvik reported robust figures, driven particularly by strong order intake within its mining segment, which supported the share price. Hexagon appreciated partly as a result of the divestment of part of its operations at an attractive valuation multiple. The main detractors from performance were Thule, Essity, and Lagercrantz. Thule faced weaker demand conditions, particularly among North American distributors, while Essity underperformed due to soft volume growth. Lagercrantz declined from elevated levels, in line with other serial acquirers.
During the period, the fund increased its exposure to the more late‑cyclical company Atlas Copco, while reducing its position in the more short‑cyclical Sandvik. The fund also exited its position in Handelsbanken, which is currently trading at a premium relative to its historical valuation.
Portfolio distribution 30.09.2025
Geographic breakdown 30.09.2025
